Two Oral GLP-1 Trials Clear Phase 2b, Crowding the Pipeline

Media partner

PHARMA · CARDIO-METABOLIC · JUNE 21, 2026 · UNITED STATES

Positive Phase 2b data for two oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — elecoglipron and aleniglipron — published simultaneously in The Lancet and Nature Medicine respectively, confirm that the class can deliver clinically relevant weight loss without the food or fluid restrictions that constrain existing oral peptide formulations. The results arrive as the obesity and type 2 diabetes treatment market faces its most congested oral pipeline in years.

The ACCESS trial, evaluating aleniglipron, reported placebo-adjusted weight loss of up to 11.3% at week 36, according to data published in Nature Medicine. Notably, the trial showed no plateau at that timepoint — a detail with direct implications for how the drug’s durability profile will be assessed in Phase 3. The SOLSTICE trial, evaluating elecoglipron, reported positive Phase 2b results published in The Lancet. Neither publication has been independently verified by a regulatory body; both represent investigator-reported trial outcomes ahead of any pivotal programme.

The absence of a fasting requirement is the operationally significant feature of both candidates. Current oral semaglutide — the only approved oral GLP-1 RA — requires administration with no more than 120 millilitres of water and a 30-minute fast before eating, a regimen that has been associated with adherence challenges in real-world settings, though the published trial data does not establish a direct causal link between those restrictions and discontinuation rates. Whether removing the restriction translates into measurably better adherence at population scale remains to be confirmed in Phase 3.

Both candidates now join orforglipron, a Eli Lilly, Indianapolis-based pharmaceutical company’s oral small-molecule GLP-1 RA, as Phase 3 candidates, according to the published materials. The convergence of three oral small-molecule programmes in overlapping development windows is a structural shift in the competitive landscape for injectable GLP-1 franchises, though the size of the addressable pool that would switch from injectable to oral formulations has not been quantified in the published trial data.

The principal friction point is the distance between Phase 2b and commercial relevance. A 36-week weight-loss signal in a Phase 2b cohort does not confirm Phase 3 success, regulatory approval, or payer coverage. The history of the GLP-1 class includes multiple candidates that demonstrated early efficacy but encountered safety signals, tolerability issues, or insufficient durability in larger, longer trials. The no-plateau finding in the ACCESS trial is analytically encouraging, but the trial duration does not yet address whether weight loss is sustained beyond 36 weeks or whether the trajectory continues, flattens, or reverses — a question that Phase 3 design will need to answer explicitly.

For payers and formulary managers, the near-term operational implication is monitoring, not action. No oral small-molecule GLP-1 RA has reached a regulatory submission in the United States, and formulary cycle timelines mean that coverage decisions remain years away for these specific candidates. The more immediate strategic question is how payers model a future formulary environment in which three oral candidates with differentiated dosing profiles compete against each other and against established injectable franchises — a scenario that could compress net pricing across the class if Phase 3 data holds.

The deeper signal in the simultaneous publication of two positive Phase 2b datasets is not efficacy confirmation — it is that the oral small-molecule GLP-1 class has reached the point where competitive dynamics within the oral segment may matter as much as the oral-versus-injectable comparison. If three candidates reach Phase 3 with overlapping timelines, the pricing and access negotiations that follow approval will be shaped by within-class competition before the first product reaches a formulary.